Innate Pharma to present updated interim Phase 2 efficacy results of lacutamab in mycosis fungoides at the international conference on malignant lymphoma

• Efficacy results of lacutamab in Mycosis Fungoides according to updated lymph node classification in the TELLOMAK Phase 2 study in advanced cutaneous T cell lymphomas 

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that interim efficacy results from the TELLOMAK Phase 2 study of lacutamab in advanced Mycosis Fungoides will be presented at the 17th International Conference on Malignant Lymphoma, being held in Lugano, June 13 – 17, 2023. Efficacy results will be presented according to updated lymph node classification.

Presentation details 

• Title: Lacutamab in patients with advanced mycosis fungoides (MF): efficacy results according to updated lymph node (LN) classification in the TELLOMAK study
• Session: Focus on…T-Cell Lymphomas
• Date and time: 15/06/2023, 17:50
• Location: Room A
• Speaker: Dr. Pierluigi Porcu, Director, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Sidney Kimmel Cancer Center, Jefferson Health Philadelphia, US

In addition, a Trial in Progress abstract of KILT, the Phase 2 study of lacutamab in peripheral T-cell lymphoma led by The Lymphoma Study Association (LYSA) has been published in the 17-ICML abstract book available online.

About Lacutamab

Lacutamab is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL). Rare cutaneous lymphomas of T lymphocytes have a poor prognosis with few efficacious and safe therapeutic options at advanced stages.

KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up 90% of patients with certain aggressive CTCL subtypes, in particular, Sézary syndrome. It is expressed by up to 50% of patients with mycosis fungoides and peripheral T-cell lymphoma (PTCL). It has a restricted expression on normal tissues.

Lacutamab is granted European Medicines Agency (EMA) PRIME designation and US Food and Drug Administration (FDA) granted Fast Track designation for the treatment of patients with relapsed or refractory Sézary syndrome who have received at least two prior systemic therapies. Lacutamab is granted orphan drug status in the European Union and in the United States for the treatment of CTCL.